CD19 and neoplasm: CXCR4 overexpression has also been combined with CARs targeting either CD19 or epidermal growth factor (EGFR)vIII in NK cells to enhance migration toward tumor cells and the retention of endogenous and CAR-mediated cytotoxic activities [68, 126].